HPV-negative Tumors in a Swedish Cohort of Cervical Cancer
Despite the common perception that the human papilloma virus (HPV) is a requirement for the development of cervical cancer (CC), a considerable number of CCs test HPV negative. Presently, many countries are shifting to HPV primary CC screening, and it is of importance to increase the knowledge about...
Uloženo v:
| Vydáno v: | International journal of gynecological pathology Ročník 39; číslo 3; s. 279 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
01.05.2020
|
| Témata: | |
| ISSN: | 1538-7151, 1538-7151 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Despite the common perception that the human papilloma virus (HPV) is a requirement for the development of cervical cancer (CC), a considerable number of CCs test HPV negative. Presently, many countries are shifting to HPV primary CC screening, and it is of importance to increase the knowledge about the group of CCs that test HPV negative. The aim of this study was to reinvestigate a proportion of cervical tumors with a primary negative or invalid test result. Reinvestigation with repeated genotyping (targeting L1) was followed by analysis with an alternative target method (targeting E6/E7) on existing or additional tumor material. Consistently negative tumors were histologically evaluated, and cases with low or lacking tumor cell content, consistent invalid test results, or with suspicion of other than cervical origin were excluded. HPV-negative cases were thereafter subjected to immunohistochemistry (Cytokeratin 5, pan cytokeratin, protein 63, P16, and P53). The HPV-negative proportion could after reinvestigation be reduced by one-half (14%-7%). Additional positive samples were often detected in late polymerase chain reaction cycles, with an alternative (E6/E7) or the same (L1) target, or with a method using shorter amplicon lengths. Confirmed HPV negativity was significantly associated with worse prognosis, high patient age, longer storage time, and adenocarcinoma histology. Some of the HPV-negative cases showed strong/diffuse p16 immunoreactivity, indicating some remaining false-negative cases. False HPV negativity in this cohort was mainly linked to methodological limitations in the analysis of stored CC material. The small proportion of presumably true HPV-negative adenocarcinomas is not a reason for hesitation in revision to CC screening with primary HPV testing. |
|---|---|
| AbstractList | Despite the common perception that the human papilloma virus (HPV) is a requirement for the development of cervical cancer (CC), a considerable number of CCs test HPV negative. Presently, many countries are shifting to HPV primary CC screening, and it is of importance to increase the knowledge about the group of CCs that test HPV negative. The aim of this study was to reinvestigate a proportion of cervical tumors with a primary negative or invalid test result. Reinvestigation with repeated genotyping (targeting L1) was followed by analysis with an alternative target method (targeting E6/E7) on existing or additional tumor material. Consistently negative tumors were histologically evaluated, and cases with low or lacking tumor cell content, consistent invalid test results, or with suspicion of other than cervical origin were excluded. HPV-negative cases were thereafter subjected to immunohistochemistry (Cytokeratin 5, pan cytokeratin, protein 63, P16, and P53). The HPV-negative proportion could after reinvestigation be reduced by one-half (14%-7%). Additional positive samples were often detected in late polymerase chain reaction cycles, with an alternative (E6/E7) or the same (L1) target, or with a method using shorter amplicon lengths. Confirmed HPV negativity was significantly associated with worse prognosis, high patient age, longer storage time, and adenocarcinoma histology. Some of the HPV-negative cases showed strong/diffuse p16 immunoreactivity, indicating some remaining false-negative cases. False HPV negativity in this cohort was mainly linked to methodological limitations in the analysis of stored CC material. The small proportion of presumably true HPV-negative adenocarcinomas is not a reason for hesitation in revision to CC screening with primary HPV testing.Despite the common perception that the human papilloma virus (HPV) is a requirement for the development of cervical cancer (CC), a considerable number of CCs test HPV negative. Presently, many countries are shifting to HPV primary CC screening, and it is of importance to increase the knowledge about the group of CCs that test HPV negative. The aim of this study was to reinvestigate a proportion of cervical tumors with a primary negative or invalid test result. Reinvestigation with repeated genotyping (targeting L1) was followed by analysis with an alternative target method (targeting E6/E7) on existing or additional tumor material. Consistently negative tumors were histologically evaluated, and cases with low or lacking tumor cell content, consistent invalid test results, or with suspicion of other than cervical origin were excluded. HPV-negative cases were thereafter subjected to immunohistochemistry (Cytokeratin 5, pan cytokeratin, protein 63, P16, and P53). The HPV-negative proportion could after reinvestigation be reduced by one-half (14%-7%). Additional positive samples were often detected in late polymerase chain reaction cycles, with an alternative (E6/E7) or the same (L1) target, or with a method using shorter amplicon lengths. Confirmed HPV negativity was significantly associated with worse prognosis, high patient age, longer storage time, and adenocarcinoma histology. Some of the HPV-negative cases showed strong/diffuse p16 immunoreactivity, indicating some remaining false-negative cases. False HPV negativity in this cohort was mainly linked to methodological limitations in the analysis of stored CC material. The small proportion of presumably true HPV-negative adenocarcinomas is not a reason for hesitation in revision to CC screening with primary HPV testing. Despite the common perception that the human papilloma virus (HPV) is a requirement for the development of cervical cancer (CC), a considerable number of CCs test HPV negative. Presently, many countries are shifting to HPV primary CC screening, and it is of importance to increase the knowledge about the group of CCs that test HPV negative. The aim of this study was to reinvestigate a proportion of cervical tumors with a primary negative or invalid test result. Reinvestigation with repeated genotyping (targeting L1) was followed by analysis with an alternative target method (targeting E6/E7) on existing or additional tumor material. Consistently negative tumors were histologically evaluated, and cases with low or lacking tumor cell content, consistent invalid test results, or with suspicion of other than cervical origin were excluded. HPV-negative cases were thereafter subjected to immunohistochemistry (Cytokeratin 5, pan cytokeratin, protein 63, P16, and P53). The HPV-negative proportion could after reinvestigation be reduced by one-half (14%-7%). Additional positive samples were often detected in late polymerase chain reaction cycles, with an alternative (E6/E7) or the same (L1) target, or with a method using shorter amplicon lengths. Confirmed HPV negativity was significantly associated with worse prognosis, high patient age, longer storage time, and adenocarcinoma histology. Some of the HPV-negative cases showed strong/diffuse p16 immunoreactivity, indicating some remaining false-negative cases. False HPV negativity in this cohort was mainly linked to methodological limitations in the analysis of stored CC material. The small proportion of presumably true HPV-negative adenocarcinomas is not a reason for hesitation in revision to CC screening with primary HPV testing. |
| Author | Bohr Mordhorst, Louise Lillsunde-Larsson, Gabriella Sorbe, Bengt Karlsson, Mats G Kaliff, Malin Helenius, Gisela |
| Author_xml | – sequence: 1 givenname: Malin surname: Kaliff fullname: Kaliff, Malin organization: Departments of Laboratory Medicine (M.K., M.G.K., G.H., G.L.-L.) Oncology (B.S., L.B.M.), Faculty of Medicine and Health, Örebro University School of Health Sciences, Örebro University (G.L.-L.), Örebro, Sweden – sequence: 2 givenname: Mats G surname: Karlsson fullname: Karlsson, Mats G – sequence: 3 givenname: Bengt surname: Sorbe fullname: Sorbe, Bengt – sequence: 4 givenname: Louise surname: Bohr Mordhorst fullname: Bohr Mordhorst, Louise – sequence: 5 givenname: Gisela surname: Helenius fullname: Helenius, Gisela – sequence: 6 givenname: Gabriella surname: Lillsunde-Larsson fullname: Lillsunde-Larsson, Gabriella |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31206367$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj01Lw0AURQep2A_9ByKzdJP63ktmkriToK1QMGB1GybJjI0kmTrTVPz3FqzQuzl3cbhwp2zU214zdo0wR0jju3yRz-E0EumMTVCESRCjwNFJH7Op958AKFHGF2wcIoEMZTxh98v8Pej1h9o1e83XQ2ed503PFX_91nXjNzyzG-t23BqeabdvKtXyTPWVdpfs3KjW66sjZ-zt6XGdLYPVy-I5e1gFlZBAQalTAkFlXEVCGpPUCkCUKo0EJjomoBpLhESgSSswtTDqIIdRFGKsSFFIM3b7t7t19mvQfld0ja9026pe28EXRBElJCmCg3pzVIey03WxdU2n3E_x_5d-Ab3xVxg |
| CitedBy_id | crossref_primary_10_3389_fonc_2024_1452834 crossref_primary_10_1093_jrr_rrac086 crossref_primary_10_17650_1726_9784_2025_24_1_27_33 crossref_primary_10_3892_ol_2022_13185 crossref_primary_10_1080_21688370_2023_2256641 crossref_primary_10_1111_apm_13265 crossref_primary_10_1038_s41571_024_00904_z crossref_primary_10_1097_PGP_0000000000001040 crossref_primary_10_3390_diagnostics12061508 crossref_primary_10_1097_LGT_0000000000000650 crossref_primary_10_1016_j_ejogrb_2021_04_040 crossref_primary_10_1038_s41416_023_02555_w crossref_primary_10_1038_s41598_021_93485_1 crossref_primary_10_1016_j_ygyno_2023_01_001 crossref_primary_10_1186_s12905_025_03555_z crossref_primary_10_3390_v16040501 crossref_primary_10_1007_s00292_021_01051_3 crossref_primary_10_1016_j_gene_2024_149103 crossref_primary_10_3390_cancers12092388 crossref_primary_10_1016_j_pathol_2025_08_001 crossref_primary_10_1093_hmg_ddac031 crossref_primary_10_3390_microorganisms9040729 crossref_primary_10_1002_ijgo_14598 crossref_primary_10_3390_diagnostics12081906 crossref_primary_10_1002_jmv_70564 crossref_primary_10_1007_s12094_025_03959_1 crossref_primary_10_3389_fonc_2021_678758 crossref_primary_10_3390_cells11233911 crossref_primary_10_1016_j_modpat_2025_100742 crossref_primary_10_1097_PAS_0000000000001778 crossref_primary_10_3390_cancers16091662 crossref_primary_10_3389_fonc_2024_1320265 crossref_primary_10_3389_fonc_2023_1264114 crossref_primary_10_1177_1721727X221128089 crossref_primary_10_1136_ijgc_2021_003159 crossref_primary_10_1097_PAS_0000000000002067 crossref_primary_10_1097_PAS_0000000000002122 crossref_primary_10_1007_s44178_024_00120_w crossref_primary_10_1136_ijgc_2021_003014 crossref_primary_10_3390_diagnostics11060952 crossref_primary_10_3390_ijms26125549 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1097/PGP.0000000000000612 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1538-7151 |
| ExternalDocumentID | 31206367 |
| Genre | Journal Article |
| GeographicLocations | Sweden |
| GeographicLocations_xml | – name: Sweden |
| GroupedDBID | --- .55 .Z2 0R~ 3O- 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS AAAAV AAHPQ AAIQE AAMTA AAQQT AARTV AASCR AAYEP ABASU ABBUW ABDIG ABJNI ABVCZ ABXVJ ABZAD ACDDN ACEWG ACGFO ACGFS ACILI ACNWC ACWDW ACWRI ACXJB ACXNZ ADFPA ADGGA ADHPY ADNKB AE3 AEETU AENEX AFDTB AFUWQ AGINI AHQNM AHRYX AHVBC AINUH AJCLO AJIOK AJNWD AJNYG AJZMW AKCTQ ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW AWKKM BQLVK BS7 C45 CGR CS3 CUY CVF DIWNM DU5 DUNZO E.X EBS ECM EEVPB EIF EJD EX3 F2K F2L F5P FCALG FL- GNXGY GQDEL H0~ HLJTE HZ~ IKREB IN~ IPNFZ JF9 JG8 JK3 JK8 K8S KD2 KMI L-C L7B NPM N~M O9- OAG OAH OCUKA ODA OJAPA OL1 OLG OLV OLW OLZ OPUJH ORVUJ OUVQU OVD OVDNE OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P R58 RIG RLZ S4R S4S T8P TEORI TSPGW V2I VVN W3M WOQ WOW X3V X3W X7M XXN XYM YFH ZFV ZGI ZZMQN 7X8 ABPXF ABZZY ADKSD AFBFQ AOQMC |
| ID | FETCH-LOGICAL-c5602-be92052b7c456ff8da005ba94518e7202d1b10851f9c0fd5fa52b344317a2a232 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 43 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000526400700012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1538-7151 |
| IngestDate | Wed Oct 01 15:03:45 EDT 2025 Wed Feb 19 02:29:47 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5602-be92052b7c456ff8da005ba94518e7202d1b10851f9c0fd5fa52b344317a2a232 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://doi.org/10.1097/pgp.0000000000000612 |
| PMID | 31206367 |
| PQID | 2242826240 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2242826240 pubmed_primary_31206367 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-May |
| PublicationDateYYYYMMDD | 2020-05-01 |
| PublicationDate_xml | – month: 05 year: 2020 text: 2020-May |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | International journal of gynecological pathology |
| PublicationTitleAlternate | Int J Gynecol Pathol |
| PublicationYear | 2020 |
| SSID | ssj0016167 |
| Score | 2.4465332 |
| Snippet | Despite the common perception that the human papilloma virus (HPV) is a requirement for the development of cervical cancer (CC), a considerable number of CCs... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 279 |
| SubjectTerms | Adenocarcinoma - pathology Adenocarcinoma - virology Adult Aged Aged, 80 and over Female Humans Middle Aged Papillomavirus Infections - epidemiology Sweden - epidemiology Uterine Cervical Neoplasms - pathology Uterine Cervical Neoplasms - virology |
| Title | HPV-negative Tumors in a Swedish Cohort of Cervical Cancer |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31206367 https://www.proquest.com/docview/2242826240 |
| Volume | 39 |
| WOSCitedRecordID | wos000526400700012&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeMhKrReI8XLMgVFE60CoSpeoW2Y5NO5CUhsLf5-wk6oSERAZPSWSd7_HZ57sPoRvBKOWCGSKp1CTkQUg4U4wYZnQgOZWR41gaP7PhsDOZ8KQ-cCvra5WNT3SOOiuUPSO_hVADu4MYAtD9_INY1iibXa0pNNZRKwAoY7WaTVZZhNh3DLLOqBmEtqZ0jrPb5CmpWhc2T2w5KX8DmS7Y9Hb_O809tFPDTPxQ6cU-WtP5Adoa1In0Q3TXT8Yk12-u7TceLd-LRYlnORb45dtW6k5xt5gCMseFwV3nTuBvXashiyP02nscdfukplEgCuAMJVJz6kVUMgVgyZhOJsDypOBh5Hc0ox7NfGlrEHzDlWeyyAh4OQgtshBUAOI6Rht5ketThL1Yat-TvooBhXgqlkHGokjFjBrQyCxro-tGKimoqc09iFwXyzJdyaWNTirRpvOqn0Ya-BSAUszO_vD1OdqmdsfrrhxeoJYBI9WXaFN9fc7KxZVbfxiHyeAHgOW2fg |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=HPV-negative+Tumors+in+a+Swedish+Cohort+of+Cervical+Cancer&rft.jtitle=International+journal+of+gynecological+pathology&rft.au=Kaliff%2C+Malin&rft.au=Karlsson%2C+Mats+G&rft.au=Sorbe%2C+Bengt&rft.au=Bohr+Mordhorst%2C+Louise&rft.date=2020-05-01&rft.eissn=1538-7151&rft.volume=39&rft.issue=3&rft.spage=279&rft_id=info:doi/10.1097%2FPGP.0000000000000612&rft_id=info%3Apmid%2F31206367&rft_id=info%3Apmid%2F31206367&rft.externalDocID=31206367 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-7151&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-7151&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-7151&client=summon |